110 related articles for article (PubMed ID: 33082275)
21. Targeting a Designer TIMP-1 to the Cell Surface for Effective MT1-MMP Inhibition: A Potential Role for the Prion Protein in Renal Carcinoma Therapy.
Jiang B; Liu J; Lee MH
Molecules; 2019 Jan; 24(2):. PubMed ID: 30641935
[TBL] [Abstract][Full Text] [Related]
22. HIV protease inhibitors selectively induce gene expression alterations associated with reduced calcium deposition in primary human osteoblasts.
Malizia AP; Cotter E; Chew N; Powderly WG; Doran PP
AIDS Res Hum Retroviruses; 2007 Feb; 23(2):243-50. PubMed ID: 17331030
[TBL] [Abstract][Full Text] [Related]
23. The HIV protease inhibitor indinavir down-regulates the expression of the pro-angiogenic MT1-MMP by human endothelial cells.
Barillari G; Iovane A; Bacigalupo I; Labbaye C; Chiozzini C; Sernicola L; Quaranta MT; Falchi M; Sgadari C; Ensoli B
Angiogenesis; 2014 Oct; 17(4):831-8. PubMed ID: 24719186
[TBL] [Abstract][Full Text] [Related]
24. [Observation of the antitumor effect of endostar combined with docetaxel under different administration sequences].
Yuan J; Wu CW; Liu ZJ; Wei XY; Li K
Zhonghua Zhong Liu Za Zhi; 2010 Aug; 32(8):580-5. PubMed ID: 21122408
[TBL] [Abstract][Full Text] [Related]
25. Expression of metalloproteinases and their inhibitors in adenocarcinoma of the uterine cervix.
Davidson B; Goldberg I; Liokumovich P; Kopolovic J; Gotlieb WH; Lerner-Geva L; Reder I; Ben-Baruch G; Reich R
Int J Gynecol Pathol; 1998 Oct; 17(4):295-301. PubMed ID: 9785129
[TBL] [Abstract][Full Text] [Related]
26. [Expression of matrix metalloproteinase-2, 9 and their inhibitor-TIMP 1,2 in human squamous cell carcinoma of uterine cervix].
Zhou CY; Yao JF; Chen XD
Ai Zheng; 2002 Jul; 21(7):735-9. PubMed ID: 12479097
[TBL] [Abstract][Full Text] [Related]
27. CD40L induces matrix-metalloproteinase-9 but not tissue inhibitor of metalloproteinases-1 in cervical carcinoma cells: imbalance between NF-kappaB and STAT3 activation.
Smola-Hess S; Schnitzler R; Hadaschik D; Smola H; Mauch C; Krieg T; Pfister H
Exp Cell Res; 2001 Jul; 267(2):205-15. PubMed ID: 11426939
[TBL] [Abstract][Full Text] [Related]
28. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy.
Lucio-Eterovic AK; Piao Y; de Groot JF
Clin Cancer Res; 2009 Jul; 15(14):4589-99. PubMed ID: 19567589
[TBL] [Abstract][Full Text] [Related]
29. Phloretin suppresses metastasis by targeting protease and inhibits cancer stemness and angiogenesis in human cervical cancer cells.
Hsiao YH; Hsieh MJ; Yang SF; Chen SP; Tsai WC; Chen PN
Phytomedicine; 2019 Sep; 62():152964. PubMed ID: 31153059
[TBL] [Abstract][Full Text] [Related]
30. Zinc finger nucleases targeting the human papillomavirus E7 oncogene induce E7 disruption and a transformed phenotype in HPV16/18-positive cervical cancer cells.
Ding W; Hu Z; Zhu D; Jiang X; Yu L; Wang X; Zhang C; Wang L; Ji T; Li K; He D; Xia X; Liu D; Zhou J; Ma D; Wang H
Clin Cancer Res; 2014 Dec; 20(24):6495-503. PubMed ID: 25336692
[TBL] [Abstract][Full Text] [Related]
31. Sprengerinin C exerts anti-tumorigenic effects in hepatocellular carcinoma via inhibition of proliferation and angiogenesis and induction of apoptosis.
Zeng KW; Li N; Dong X; Ma ZZ; Jiang Y; Jin HW; Tu PF
Eur J Pharmacol; 2013 Aug; 714(1-3):261-73. PubMed ID: 23684542
[TBL] [Abstract][Full Text] [Related]
32. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
33. Antitumor activities of synthetic and natural stilbenes through antiangiogenic action.
Kimura Y; Sumiyoshi M; Baba K
Cancer Sci; 2008 Oct; 99(10):2083-96. PubMed ID: 19016770
[TBL] [Abstract][Full Text] [Related]
34. [Pathologic study of expression and significance of matrix metalloproteinases-9, tissue inhibitor of metalloproteinase-1, vascular endothelial growth factor and transforming growth factor beta-1 in papillary carcinoma and follicular carcinoma of thyroid].
Wang T; Jiang CX; Li Y; Liu X
Zhonghua Bing Li Xue Za Zhi; 2009 Dec; 38(12):824-8. PubMed ID: 20193458
[TBL] [Abstract][Full Text] [Related]
35. Ensnaring membrane type 1-matrix metalloproteinase (MT1-MMP) with tissue inhibitor of metalloproteinase (TIMP)-2 using the haemopexin domain of the protease as a carrier: a targeted approach in cancer inhibition.
Jiang B; Zhang Y; Liu J; Tsigkou A; Rapti M; Lee MH
Oncotarget; 2017 Apr; 8(14):22685-22699. PubMed ID: 28186971
[TBL] [Abstract][Full Text] [Related]
36. [Expressions of receptor-binding cancer antigen expressed on SiSo cells, vascular endothelial growth factor, and matrix metalloproteinase-9 in cervical carcinoma and correlation thereof with the invasion and metastasis of the cancerous tissues].
Liu R; Pu DM; Cheng YX; Yin L
Zhonghua Yi Xue Za Zhi; 2007 May; 87(19):1326-9. PubMed ID: 17727777
[TBL] [Abstract][Full Text] [Related]
37. Anti-invasive effect of MMI-166, a new selective matrix metalloproteinase inhibitor, in cervical carcinoma cell lines.
Iwasaki M; Nishikawa A; Fujimoto T; Akutagawa N; Manase K; Endo T; Yoshida K; Maekawa R; Yoshioka T; Kudo R
Gynecol Oncol; 2002 Apr; 85(1):103-7. PubMed ID: 11925127
[TBL] [Abstract][Full Text] [Related]
38. Secreted MMP9 promotes angiogenesis more efficiently than constitutive active MMP9 bound to the tumor cell surface.
Mira E; Lacalle RA; Buesa JM; de Buitrago GG; Jiménez-Baranda S; Gómez-Moutón C; Martínez-A C; Mañes S
J Cell Sci; 2004 Apr; 117(Pt 9):1847-57. PubMed ID: 15075244
[TBL] [Abstract][Full Text] [Related]
39. The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer.
Inglis DJ; Lavranos TC; Beaumont DM; Leske AF; Brown CK; Hall AJ; Kremmidiotis G
Cancer Biol Ther; 2014; 15(11):1552-60. PubMed ID: 25482941
[TBL] [Abstract][Full Text] [Related]
40. Lopinavir up-regulates expression of the antiviral protein ribonuclease L in human papillomavirus-positive cervical carcinoma cells.
Batman G; Oliver AW; Zehbe I; Richard C; Hampson L; Hampson IN
Antivir Ther; 2011; 16(4):515-25. PubMed ID: 21685539
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
